Lake Street raised the firm’s price target on Personalis (PSNL) to $9 from $7 and keeps a Buy rating on the shares after the company reported preliminary Q4 revenue ahead the firm’s estimate and consensus. With cash to breakeven, a strong commercial partner, “robust” clinical data, and the potential for multiple reimbursement approvals, the firm views 2025 as “another transformative year” for Personalis, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Personalis reports preliminary Q4 revenue $16.8M, consensus $15.5M
- Personalis raises FY24 revenue view to $84.6M from $83M-$84M
- Personalis up 3% at $6.15 after Q4 pre-announcement, FY24 guidance increase
- Personalis price target raised to $8 from $7 at BTIG
- Personalis price target raised to $11 from $9 at H.C. Wainwright